Amgen Inc. is halting a study of an experimental drug for reoccurring pancreatic cancer due to disappointing results. The Associated Press reports that a board of medical experts recommended that the Thousand Oaks biotech end the trial because the drug, ganitumab, appears unlikely to help patients live longer.

For reprint and licensing requests for this article, CLICK HERE.